Musculoskeletal Disorders

News from the FDA/CDC

FDA approves first tocilizumab biosimilar

Tocilizumab-bavi (Tofidence) will offer a lower-cost option for patients with autoimmune conditions, the drug manufacturer, Biogen, stated.


Humira biosimilars: Five things to know

The launch of eight adalimumab biosimilars so far in 2023 ended Humira’s 20-year monopoly, but it’s not clear yet if these discounted drugs will...